Call for Abstracts
Call for Abstracts
Abstract Submission Guidelines
- Online only submission accepted – No fax nor email is accepted. Abstracts must be submitted in English (use UK English spelling).
- The presenting author of an accepted abstract must register and attend the congress.
- If your abstract has been accepted as poster presentation, you will be asked to prepare a poster in paper and electronic format (ePoster). If your abstract has been accepted as an ePoster only, you will be asked to prepare just an electronic format (ePoster). Guidelines will follow based on acceptance of your abstract. Presenting authors of a poster presentation will present their posters in sessions during the congress.
- Abstracts should contain only original material not published or presented elsewhere prior to 23 September 2025.
- Provide a short specific title indicating the nature of the investigation. The introduction and objectives/aims of the study should appear clearly to the reader. The methods and results must contain data, and the conclusions should be clearly expressed.
- Case reports are generally discouraged. Exceptions may be considered if the case report offers significant insights or contributes uniquely to the field.
- The title may not exceed 250 characters including spaces.
- The abstract text may not be longer than 2556 characters (approx. 300 words) including headlines and spaces, excluding disclosures.
- All abbreviations, exept MS, must be defined the first time they appear in your text (but do not define in the title). Example: MS Impact Scale (MSIS), before being used as an abbreviation only.
- Generic drug names should be used
- Do not include tables, charts or other graphics. These will be deleted by the editors.
- Authors should indicate their presentation type preference: oral or poster presentation / poster presentation only
—> Note: “poster presentation only” implies that your abstract will be considered for poster presentation only.
- The Scientific Programme Committee reserves the right to decide on the final allocation and presentation method.
- An author may give only one oral presentation from submitted abstracts. If an author has multiple oral presentations, they will be contacted to decide which abstract they will present and who from the co-authors will present the others. If no co-author can present, the abstract will not be considered for oral presentation.
- A selected number of abstracts will be accepted for oral presentation based on their scientific merits and on their relation to the topics addressed in the scientific programme of the Congress. We therefore encourage submissions on the main topics covered in the scientific programme.
- Disclosure of potential conflict of interest (e.g. grant support, consultancy, membership on advisory councils, speaker’s bureau) by all authors and source of funding are mandatory. Each listed author should prepare a one sentence statement that will be published with the abstract. All disclosures should be listed for the last 3 years.
- Abstracts from commercial entities are allowed but must include independent investigators (e.g., academics, clinicians, or scientists) as authors. Only abstracts presented by an independent investigator will be accepted.
- Ensure your email address is correct. After submission, you will receive a confirmation email with a PDF of your abstract and an abstract number for reference. If no confirmation is received, contact ectrims.abstracts@congrex.com.
Correction of abstracts
You can make adjustments until the abstract submission deadline. No changes will be possible after the deadline.
Picture of presenting author
We kindly request that you upload a photo of the presenting author to your account. The photo should be in JPG or GIF format and no larger than 1 MB. Once selected as the presenting author, please log in to your online registration account and upload the photo accordingly.
Notification
Notification of acceptance or rejection of submitted abstracts will be sent to the corresponding authors via email in June 2025. Full instructions concerning preparation and presentation will be included.
Publication
All accepted abstracts (incl. Late Breaking Abstract) will be published in the online supplement of the Multiple Sclerosis Journal as well as on the ECTRIMS 2025 Congress’s website, mobile app and on the congress platform. Full text of regular abstracts will be published 14 days prior to the congress on the congress website. Late Breaking Abstracts will be published on the first day of the congress.
Young Scientific Investigator's Session
Abstracts submitted by presenting authors who are aged 35 or younger and for interrupted study time due to maternity/caring parents or other justified time off the clock, may be considered for the Young Scientific Investigators’ Sessions. Selected presenters will be invited to give an oral presentation followed by a discussion.
If you wish to be considered for this session, please click the appropriate checkbox during the online abstract submission process.
You will be required to upload a copy of your passport with readily readable date of birth as proof of eligibility, or a copy of your maternity leave certification or other justified cause certification. Prepare this document in one of the following formats: BMP, GIF, JPG or PDF files (size limit 1 MB). Applications without passport copy or arriving after the submission deadline will not be considered.
Need Assistance?
Please email the abstract team at ectrims.abstracts@congrex.com for questions regarding abstracts and for technical assistance. In your message, please refer to the name of the congress.
Abstract hotline: +41 61 686 77 22 (Monday – Friday during CET business hours)